Profound Medical Dirección

Dirección controles de criterios 4/4

El CEO de Profound Medical es Arun Menawat , nombrado en Aug 2016, tiene una permanencia de 8.25 años. compensación anual total es $889.95K, compuesta por 41.6% salario y 58.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.2% de las acciones de la empresa, por valor de $3.95M. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 5.2 años, respectivamente.

Información clave

Arun Menawat

Chief Executive Officer (CEO)

US$889.9k

Compensación total

Porcentaje del salario del CEO	41.6%
Permanencia del CEO	8.3yrs
Participación del CEO	2.2%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	5.2yrs

Actualizaciones recientes de la dirección

Recent updates

Profound Medical Q2 GAAP EPS beats, revenue in-line

Aug 04

Profound Medical Lacks Conviction To Overthrow Macro Headwinds

Jul 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Arun Menawat en comparación con los beneficios de Profound Medical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$28m
Dec 31 2023	US$890k	US$370k	-US$29m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$916k	US$344k	-US$29m
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$30m
Mar 31 2022	n/a	n/a	-US$31m
Dec 31 2021	US$4m	US$481k	-US$31m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$26m
Dec 31 2020	US$2m	US$1m	-US$22m
Sep 30 2020	n/a	n/a	-US$18m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$2m	US$531k	-US$15m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	n/a	n/a	-US$14m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$672k	US$509k	-US$15m
Sep 30 2018	n/a	n/a	-US$16m
Jun 30 2018	n/a	n/a	-US$16m
Mar 31 2018	n/a	n/a	-US$15m
Dec 31 2017	US$264k	US$264k	-US$15m

Compensación vs. Mercado: La compensación total de Arun($USD889.95K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD1.46M).

Compensación vs. Ingresos: La compensación de Arun ha sido consistente con los resultados de la empresa en el último año.

CEO

Arun Menawat (69 yo)

8.3yrs

Permanencia

US$889,948

Compensación

Dr. Arun Swarup Menawat, Ph D., MBA, served as the Chairman at Firefly Neuroscience, Inc. and is its Independent Director. He serves as the Chairman at Profound Medical Corp. Dr. Menawat has been the Chief...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Arun Menawat	Chairman of the Board & CEO	8.3yrs	US$889.95k	2.2% $ 4.0m
Rashed Dewan	Chief Financial Officer	3.5yrs	US$669.26k	0.19% $ 340.7k
Mathieu Burtnyk	Chief Operating Officer	less than a year	US$396.81k	0.13% $ 234.6k
Stephen Kilmer	Investor Relations	no data	sin datos	sin datos
Thomas Tamberrino	Chief Commercial Officer	less than a year	sin datos	sin datos
Matthew Sobczyk	Assistant Corporate Controller	no data	sin datos	sin datos
Levant Tinaz	Software Developer	no data	sin datos	sin datos

2.1yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PROF se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Arun Menawat	Chairman of the Board & CEO	9.4yrs	US$889.95k	2.2% $ 4.0m
Arthur L. Rosenthal	Independent Director	6.4yrs	US$101.96k	0.070% $ 125.8k
Brian Ellacott	Independent Lead Director	6.4yrs	US$102.91k	0.28% $ 494.5k
Cynthia Lavoie	Independent Director	3.7yrs	US$97.91k	0.024% $ 43.6k
Mark Emberton	Member of Clinical Advisory Board	no data	sin datos	sin datos
Murielle Lortie	Independent Director	4yrs	US$100.41k	0.013% $ 22.9k
Eric Klein	Member of Clinical Advisory Board	no data	sin datos	sin datos
Laurence Klotz	Member of Clinical Advisory Board	2.1yrs	sin datos	sin datos
Scott Eggener	Member of Clinical Advisory Board	no data	sin datos	sin datos
Adam Kibel	Member of Clinical Advisory Board	no data	sin datos	sin datos
Aytekin Oto	Member of Clinical Advisory Board	no data	sin datos	sin datos
Ian Thompson	Member of Clinical Advisory Board	no data	sin datos	sin datos

5.2yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de PROF se considera experimentada (5.2 años de antigüedad promedio).

Profound Medical Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Chief Financial Officer recently bought US$92k worth of stock

Chief Commercial Officer of US recently sold US$70k worth of stock

Profound Medical Corp., Annual General Meeting, May 15, 2024

Chairman & CEO recently bought US$101k worth of stock

Profound Medical Corp. Announces Changes to Commercial Organization to Support Continued Growth

Independent Director recently bought US$98k worth of stock

Recent updates

Profound Medical Corp. to Report Q3, 2024 Results on Nov 07, 2024

Chief Financial Officer recently bought US$92k worth of stock

New minor risk - Profitability

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Profound Medical Corp. to Report Q2, 2024 Results on Aug 08, 2024

Price target increased by 7.1% to US$13.83

Profound Medical Corp. Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan

Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024

Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.32 loss in 1Q 2023)

Forecast to breakeven in 2026

Profound Medical Corp. to Report Q1, 2024 Results on May 09, 2024

Chief Commercial Officer of US recently sold US$70k worth of stock

Profound Medical Corp., Annual General Meeting, May 15, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Profound Medical Corp. to Report Q4, 2023 Results on Mar 07, 2024

Profound Medical Corp. announced that it expects to receive $2.937503 million in funding

Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

Price target decreased by 8.1% to US$14.19

Profound Medical Corp. Announces CMD Extension of Temporary Code for TULSA to ASC Setting

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Profound Medical Corp. to Report Q3, 2023 Results on Nov 02, 2023

Profound Medical Corp. Receives U.S. FDA 510(k) Clearance for TULSA-PRO Thermal Boost

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Profound Medical Corp. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Shareholder dilution

New minor risk - Share price stability

Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Profound Medical Corp. to Report Q4, 2022 Results on Mar 07, 2023

Chairman & CEO recently bought US$101k worth of stock

Price target decreased to US$10.34

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.53

Profound Medical Corp. to Report Q3, 2022 Results on Nov 03, 2022

Profound Medical Corp. Announces Updated Results from the TACT (TULSA-PRO® Ablation Clinical Trial)

Profound Medical Corp. Announces Changes to Commercial Organization to Support Continued Growth

Profound Medical Corp. Provides TULSA-PRO Reimbursement Update

Price target decreased to US$14.15

Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.35 loss in 2Q 2021)

Profound Medical Q2 GAAP EPS beats, revenue in-line

Profound Medical Corp. to Report Q2, 2022 Results on Aug 04, 2022

Profound Medical Lacks Conviction To Overthrow Macro Headwinds

Independent Director recently bought US$98k worth of stock

Profound Medical Corp. Elects Kris Shah to Board of Director

Profound Medical Corp. Unveils TULSA-PRO Software Release 2.11, Which Includes Two New Features

Independent Lead Director recently bought US$353k worth of stock

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Profound Medical Corp. to Report Q1, 2022 Results on May 09, 2022

Chairman & CEO recently bought US$497k worth of stock

Forecast to breakeven in 2024

Price target decreased to US$21.64

No longer forecast to breakeven

Profound Medical Corp. Confirms the TULSA-PRO Systems New Compatibility with GE Healthcares 3T

Profound Medical Corp. to Report Q4, 2021 Results on Mar 03, 2022

Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the Tulsa Procedure to Radical Prostatectomy

Forecast to breakeven in 2024

Chairman & CEO recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.33 loss in 3Q 2020)

Price target decreased to US$25.49

Independent Director recently bought US$100k worth of stock

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.33 loss in 2Q 2020)

No longer forecast to breakeven